Free Trial

CureVac Q1 2023 Earnings Report

CureVac logo
$2.80 -0.05 (-1.75%)
As of 04:00 PM Eastern

CureVac EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.29
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

CureVac Revenue Results

Actual Revenue
$7.65 million
Expected Revenue
$16.45 million
Beat/Miss
Missed by -$8.80 million
YoY Revenue Growth
N/A

CureVac Announcement Details

Quarter
Q1 2023
Time
N/A
Remove Ads

CureVac Earnings Headlines

CureVac Wins Patent Ruling Against BioNTech
DOGE could send 6 AI stocks through the roof
Stay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement from Elon any day now … Thousands of government jobs could be replaced … By a new form of AI. Recently perfected by Musk and his team at xAI.
See More CureVac Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email.

About CureVac

CureVac (NASDAQ:CVAC) N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

View CureVac Profile

More Earnings Resources from MarketBeat